#M&A

Monro’s board has started a strategic review that could lead to acquisitions, refinancing, asset sales, or a sale of the company, opening a new chapter for the automotive service retailer.

Amneal Pharmaceuticals has agreed to acquire a biosimilar maker for $375 million upfront, highlighting how manufacturers are still using targeted deals to widen portfolios and strengthen their position in harder-to-proc

Eli Lilly’s agreement to acquire CrossBridge Bio for up to $300 million highlights continued appetite for targeted oncology assets, even at the small-company end of biotech dealmaking.

Neurocrine Biosciences is buying Soleno Therapeutics for $2.9 billion, gaining an approved treatment for a rare disease associated with insatiable hunger.

Shardul Shah of Index Ventures breaks down Google's record $32 billion acquisition of cybersecurity firm Wiz and what it reveals about the future of cloud security competition.